CENTANNI, Stefano
 Distribuzione geografica
Continente #
NA - Nord America 69
AS - Asia 51
EU - Europa 37
SA - Sud America 7
Continente sconosciuto - Info sul continente non disponibili 1
Totale 165
Nazione #
US - Stati Uniti d'America 66
SG - Singapore 41
IT - Italia 23
BR - Brasile 6
GB - Regno Unito 6
DE - Germania 3
HK - Hong Kong 2
LT - Lituania 2
MX - Messico 2
VN - Vietnam 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
AZ - Azerbaigian 1
BD - Bangladesh 1
CA - Canada 1
FI - Finlandia 1
IQ - Iraq 1
JP - Giappone 1
NL - Olanda 1
PK - Pakistan 1
PL - Polonia 1
UY - Uruguay 1
Totale 165
Città #
Singapore 28
Santa Clara 11
Milan 8
New York 4
Chicago 3
Lawrence 3
Muggiò 3
Munich 3
Princeton 3
Rome 3
San Francisco 3
Ashburn 2
Assago 2
Atlanta 2
Brooklyn 2
Campobasso 2
Des Moines 2
Hong Kong 2
London 2
Palermo 2
San Nicola Manfredi 2
Baku 1
Boa Vista 1
Carandaí 1
Charlotte 1
Cincinnati 1
Corpus Christi 1
Dubai 1
Harrisburg 1
Ho Chi Minh City 1
Itanhém 1
Legnago 1
Los Angeles 1
Maldonado 1
Mesquite 1
Mexico City 1
Ninh Bình 1
Norwalk 1
Nova Iguaçu 1
Philadelphia 1
Phoenix 1
Preston 1
Rhyl 1
Seattle 1
São Paulo 1
São Pedro 1
The Dalles 1
Tokyo 1
Turku 1
Warsaw 1
Wilmington 1
Totale 122
Nome #
Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study 22
Chronic rhinosinusitis with nasal polyps impact in severe asthma patients: Evidences from the Severe Asthma Network Italy (SANI) registry 22
Benralizumab in Patients With Severe Eosinophilic Asthma With and Without Chronic Rhinosinusitis With Nasal Polyps: An ANANKE Study post-hoc Analysis 19
Point-of-Care Lung Sonography: An Audit of 1150 Examinations 17
ChAracterization of ItaliaN severe uncontrolled Asthmatic patieNts Key features when receiving Benralizumab in a real-life setting: the observational rEtrospective ANANKE study 16
Reply to: Kow CS et al. Are severe asthma patients at higher risk of developing severe outcomes from COVID-19? 15
Clinical Features and Efficacy of Benralizumab in Patients with Blood Eosinophil Count Between 300 and 450 Cells/mm3: A Post Hoc Analysis from the ANANKE Study 13
Switching from one biologic to benralizumab in patients with severe eosinophilic asthma: An ANANKE study post hoc analysis 13
Sustained Effectiveness of Benralizumab in Naïve and Biologics-Experienced Severe Eosinophilic Asthma Patients: Results from the ANANKE Study 11
COVID-19 in Severe Asthma Network in Italy (SANI) patients: Clinical features, impact of comorbidities and treatments 11
Lung Ultrasound B Lines: Etiologies and Evolution with Age 10
Profiling severe asthma: Any relevance for age? An analysis from Severe Asthma Network Italy (SANI) cohort 6
Durability of benralizumab effectiveness in severe eosinophilic asthma patients with and without chronic rhinosinusitis with nasal polyps: a post hoc analysis from the ANANKE study 5
Totale 180
Categoria #
all - tutte 3.222
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.222


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212 0 2 0 0 0 0 0 0 0 0 0 0
2021/20228 0 0 0 0 0 0 2 2 0 1 3 0
2022/202310 6 0 0 1 1 1 0 1 0 0 0 0
2023/202425 5 1 3 0 0 5 1 2 0 3 5 0
2024/202588 16 2 3 1 2 13 14 5 1 2 17 12
2025/202646 34 12 0 0 0 0 0 0 0 0 0 0
Totale 180